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INTRODUCTION: In obsessive-compulsive disorder, early treatment discontinuation can hamper the effectiveness of
first-line treatments.
OBJECTIVE: This study aimed to investigate the clinical correlates of early treatment discontinuation among
obsessive-compulsive disorder patients.
METHODS: A group of patients who stopped taking selective serotonin reuptake inhibitors (SSRIs) or stopped
participating in cognitive behavioral therapy before completion of the first twelve weeks (total n=41; n=16 for
cognitive behavioral therapy and n=25 for SSRIs) were compared with a paired sample of compliant patients
(n=41). Demographic and clinical characteristics were obtained at baseline using structured clinical interviews. Chi-
square and Mann-Whitney tests were used when indicated. Variables presenting a p value ,0.15 for the difference
between groups were selected for inclusion in a logistic regression analysis that used an interaction model with
treatment dropout as the response variable.
RESULTS: Agoraphobia was only present in one (2.4%) patient who completed the twelve-week therapy, whereas it
was present in six (15.0%) patients who dropped out (p=0.044). Social phobia was present in eight (19.5%) patients
who completed the twelve-week therapy and eighteen (45%) patients who dropped out (p=0.014). Generalized
anxiety disorder was present in eight (19.5%) patients who completed the twelve-week therapy and twenty (50%)
dropouts (p=0.004), and somatization disorder was not present in any of the patients who completed the twelve-
week therapy; however, it was present in six (15%) dropouts (p=0.010). According to the logistic regression model,
treatment modality (p=0.05), agoraphobia, the Brown Assessment of Beliefs Scale scores (p=0.03) and the Beck
Anxiety Inventory (p=0.02) scores were significantly associated with the probability of treatment discontinuation
irrespective of interactions with other variables.
DISCUSSION AND CONCLUSION: Early treatment discontinuation is a common phenomenon in obsessive-compulsive
disorder patients from our therapeutic setting. Psychiatric comorbidities were associated with discontinuation rates
of specific treatments. Future studies might use this information to improve management for increased compliance
and treatment effectiveness.
KEYWORDS: Obsessive-compulsive disorder; Anxiety disorders; Somatoform disorders; First-line treatments; Patient
compliance.
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INTRODUCTION
For the majority of obsessive-compulsive disorder (OCD)
patients enrolled in controlled clinical trials, the use of
selective serotonin reuptake inhibitors (SSRIs) or cognitive
behavioral therapy (CBT) results in treatment success.
1 The
treatment success reported in controlled trials, however,
may not be generalizable to clinical practice because of low
treatment availability, high disease heterogeneity and low
completion rates.
2-4
A recent practical clinical trial for OCD showed comple-
tion rates for pharmacological and psychotherapeutic
interventions that were much lower than those reported in
previous controlled trials. Low completion rates were due to
early treatment discontinuation (before twelve weeks of
treatment) and were associated with low response rates.
5
Reasons for treatment discontinuation can be intrinsic
(related to the patient), or extrinsic (related to social
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387conditions and treatment characteristics, e.g., medication
side effects). Intrinsic factors can include psychiatric
comorbidities,
6 symptom characteristics,
7 disease severity,
8
and personality traits.
9 Understanding the reasons for early
treatment interruption is essential for the delineation of
more effective therapeutic strategies. In addition, the factors
associated with the discontinuation of psychotherapeutic
treatment might be different from those associated with the
discontinuation of pharmacological treatment. Therefore,
clarifying which factors are associated with noncompliance
could help clinicians recognize and prescribe the treatment
option that provides the greatest chance of compliance in a
given patient.
Using a recently completed clinical trial as a test case, the
objective of the present study was to determine whether
there are clinical characteristics (with an emphasis on
psychiatric comorbidities) associated with the early inter-
ruption of pharmacological or psychotherapeutic treat-
ment.
5
MATERIALS AND METHODS
The present study was part of a larger treatment study
conducted at an OCD outpatient clinic at the University of
Sao Paulo School of Medicine - Hospital das Clı ´nicas. We
received local Institutional Review Board approval before
inclusion of the first patient, and our methods followed the
Code of Ethics of the World Medical Association
(Declaration of Helsinki). Recruitment occurred between
January 2006 and December 2007 with television advertise-
ments, radio spots and newspaper announcements. A
psychologist with extensive experience in OCD contacted
the interested subjects to determine whether a diagnosis of
OCD was likely. Initial selection criteria were patients with
a probable diagnosis of OCD, who were not currently
receiving appropriate treatment, but were seeking such
treatment. Interested patients were scheduled for a psychia-
tric consultation during which eligible patients were invited
to participate in the trial.
Subjects
The inclusion criteria were a primary diagnosis of OCD
according to the DSM-IV criteria and current symptoms
causing significant distress (Yale-Brown Obsessive
Compulsive Scale (YBOCS) . or = 16). Exclusion criteria
included clinical or neurological disease that could be
worsened by the drugs used in the treatment protocol,
substance dependence, psychotic symptoms, risk for sui-
cide, and pregnancy or intention to become pregnant.
Treatment discontinuation was defined as treatment
interruption prior to the end of the twelve-week treatment
period. Treatment interruption included the failure to
initiate treatment after allocation was performed (patients
who missed the first consultation/therapy session and were
marked as ‘‘did not receive intervention’’ in figure 1), the
failure to comply with scheduled visits, or the inability to
tolerate medication side effects leading to an aversion to any
psychopharmacological treatment alternative. Patients who
were removed from the trial because of a clinical decision
(e.g., perceived clinical risk) and patients who did not
tolerate the SSRI that was initially prescribed but agreed to
take another SSRI were not considered dropouts, but they
were excluded from the analysis.
The dropout group was compared with a paired sample
of patients who completed the twelve weeks of treatment
(the completer group). Patients in the completer group were
matched to those in the dropout group in terms of age, sex,
first treatment assigned, and period of enrollment.
Figure 1 presents the flow chart.
Among the one hundred four patients allocated to receive
an SSRI, nine did not report for the initial consultation, and
thirty failed to complete the treatment. Only six patients
allocated to receive an SSRI discontinued treatment due to
side effects and did not tolerate a second SSRI; they were
classified as dropouts. Six patients were excluded due to an
interruption decision based on clinical risk, and eight were
excluded for not having completed the baseline interviews
before treatment discontinuation. Twenty-five of the
patients who abandoned SSRI treatment had completed
the baseline clinical interviews.
Among the eighty-three patients allocated to receive
group CBT, eleven did not report for the initial consultation,
and sixteen failed to complete treatment. Of the twenty-
seven patients in the CBT group who dropped out, only
sixteen had completed the baseline clinical interviews.
Therefore, the dropout group consisted of forty-one
patients (twenty-five who abandoned SSRI treatment and
sixteen who abandoned CBT).
After describing the study to the participants, we
obtained written informed consents.
Treatment
Patients who agreed to participate were sequentially
allocated to receive an SSRI or group CBT. We used a
method of sequential allocation that was devised by
Fossaluza et al.,
10 which shares the objectives of previous
minimization procedures.
11 Briefly, this method minimizes
the possibility of differences between groups in a clinical
trial that evaluates treatment efficacy by controlling for
possible confounders, such as initial Y-BOCS score, gender,
age, and previous treatment history. The advantage of the
sequential allocation method is that it provides a mechan-
ism to balance samples between group treatments.
To simulate the experience of naturalistic clinical settings,
patients allocated to receive an SSRI were preferentially
treated with fluoxetine, which is the most frequently used
SSRI in Brazilian psychiatric clinical settings, and medical
appointments were scheduled every four weeks during the
first year of the trial. Patients were allowed unlimited
telephone access to a psychiatrist. The potential side effects
and the delayed onset of therapeutic effects were explained
in detail at the first consultation. Patients were instructed to
increase their fluoxetine dosage by 20 mg per week for the
first month until the maximum tolerated dosage or 80 mg/
day was reached.
Intolerable side effects were managed by reducing the
dosage and administering symptomatic medication. If side
effects persisted at the subsequent consultation, a second
SSRI (sertraline) was used (n=6) in the place of fluoxetine.
A twelve-week group course using CBT was adminis-
tered in weekly 2-h sessions with up to 10 patients per
group. Additional information on the structured protocol
employed can be found in the study conducted by Cordioli
et al.
12
Prior to treatment initiation, patients were evaluated
using the following instruments:
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patient edition,
13 Structured Clinical Interview for Impulsive
Disorders adapted from DSM-IV criteria (available upon
request)
The Yale-Brown Obsessive-Compulsive Scale
14
The Dimensional Yale-Brown Obsessive-Compulsive Scale
15
The Brown Assessment of Beliefs Scale (BABS)
16
The Beck Anxiety Inventory (BAI)
17
The Beck Depression Inventory (BDI)
18
The Social Adjustment Scale (SAS).
19
Interviews were performed by experienced clinical psy-
chiatrists or psychologists who had junior interviewer in at
least three training sessions involving videotaped inter-
views and five involving live interviews performed by the
senior interviewer. After this training, each junior inter-
viewer conducted five interviews under the supervision of
the senior interviewer. If there was agreement between the
junior and senior interviewer on most of the results, the new
interviewer was allowed to conduct interviews without
assistance.
Statistical analysis
The dropout and completer groups were compared using
the chi-square test for categorical variables and the Mann-
Whitney test for continuous variables. Variables with a
p value , 0.15 with respect to the difference between
Figure 1 - Group cognitive behavioral therapy (GCBT).
aReasons for exclusion were not having OCD as the primary diagnosis (n=29), refusal to participate (n=15), already receiving
appropriate treatment (n=7), Yale-Brown Obsessive-Compulsive Scale score lower than 16 (n=10), suicide risk (n=2), or refractory to
multiple previous treatments (n=2).
bSequential allocation methodology has been described elsewhere.
10
cReasons for treatment discontinuation were failure to attend clinical consultations or therapy sessions (n=35), intolerable side effects
to more than one medication (n=6), medication-induced hypomania (n=2), suicide attempt (n=1), development of paranoid
symptoms regarding psychotherapy (n=2), and severe alcohol abuse during treatment (n=1).
dAnalysis included all patients who abandoned treatment after sequential allocation. Exclusions were due to noncompletion of clinical
interviews before treatment abandonment (n=19) and treatment interruption based on clinical risk rather than treatment
abandonment (n=6).
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regression analysis where dropping out was the response
variable.
The logistic regression model was adjusted to estimate the
chance of a specific patient abandoning treatment before
completing the twelve weeks of the trial. We constructed the
following formula, which considered the main effects and
first-order interactions:
log
h
1{h

~b0zb1X1z:::zbkXkzb12X1X2zb13X1X3z::: ,
where h is the chance that a patient will abandon treatment,
Xi is the ith variable, b0 is the intercept, bi is the main effect
of the ith variable, and bij is the interaction effect between
the ith variable and the jth variable; i,j=1,...,k, j,i. The
variables included in the model were chosen using the
stepwise method, and they were based on the Akaike
Information Criterion, which is a measure of the goodness of
fit of an estimated statistical model.
Only current diagnoses were entered in the analysis.
RESULTS
The comparisons between groups regarding demographic
characteristics, age at obsessive compulsive symptoms
onset, duration of illness, and OCD symptoms content are
shown in Table I.
The groups did not differ in terms of sociodemographic
characteristics or OCS content. Except for the higher severity
of anxiety symptoms in the dropout group (measured with
the BAI), there were no significant differences between
groups for any of the measures of symptom severity.
Interestingly, there was a tendency for lower insight in the
dropout group, which was measured by the BABS
(p=0.074).
Differences in Axis I psychiatric comorbidities between
groups are shown in Table II.
There were significant differences between the two
groups in terms of agoraphobia, social phobia, generalized
anxiety disorder (GAD), and somatization disorder. Indeed,
all of these disorders were more common in the dropout
group. No significant differences were found for other
psychiatric disorders.
Table I - Demographic and clinical characteristics.
Characteristic* Completers Dropouts p{
Males:Females, n (%):n (%) 23 (56.1):18 (43.9) 23 (56.1):18 (43.9) NA
Age (years), mean (SD) 33.8 (9.83) 33 (10.74) NA
First treatment assigned
SSRI, n (%) 25 (61) 25 (61) NA
Group CBT, n (%) 16 (39) 16 (39) NA
Marital status 0.122
Married, n (%) 20 (48.8) 11 (26.8)
Divorced, n (%) 3 (7.3) 4 (9.8)
Single, n (%) 18 (43.9) 26 (63.4)
Socioeconomic level 0.490
Upper class, n (%) 1 (2.4) 3 (7.7)
Middle class, n (%) 35 (85.4) 30 (76.9)
Lower class, n (%) 5 (12.2) 6 (15.4)
Employment status 0.439
Currently employed, n (%) 25 (61) 29 (70.7)
Other**, n (%) 16 (39) 12 (29.3)
Years of schooling, mean (SD) 13.7 (3.63) 13.3 (4.94) 0.703
Age at symptom onset (years), mean (SD) 15.1 (8.89) 12.3 (6.86) 0.159
Interval between symptom onset and first treatment received
(years), mean (SD)
16.0 (12.60) 17.8 (11.85) 0.549
Duration of illness (years), mean (SD) 18.7 (12.02) 20.7 (11.46) 0.444
Symptoms, by dimension (DY-BOCS)
Aggression, n (%) 26 (63.4) 30 (73.2) 0.342
Sexual and religious, n (%) 24 (58.5) 25 (61.0) 0.822
Symmetry and ordering, n (%) 37 (90.2) 36 (87.8) 0.724
Contamination and cleaning, n (%) 33 (80.5) 30 (73.2) 0.432
Hoarding, n (%) 19 (46.3) 20 (48.8) 0.825
Miscellaneous, n (%) 38 (92.7) 39 (97.5) 0.317
Beck Depression Inventory score, mean (SD) 17.4 (10.96) 21.3 (12.19) 0.147
Beck Anxiety Inventory score, mean (SD) 15.2 (9.94) 20.6 (11.45) 0.030
Social Adjustment Scale score, mean (SD) 2.3 (0.74) 2.4 (0.66) 0.197
BABS score, mean (SD) 4.2 (3.55) 6.8 (6.04) 0.074
DY-BOCS Global Severity score, mean (SD) 8.8 (1.34) 8.7 (1.90) 0.660
DY-BOCS Global Impairment score, mean (SD) 10.0 (3.10) 10.2 (2.69) 0.672
Y-BOCS obsessions score, mean (SD) 12.7 (2.93) 12.4 (3.26) 0.615
Y-BOCS compulsions score, mean (SD) 12.6 (2.67) 12.6 (3.24) 0.873
Overall Y-BOCS score, mean (SD) 25.3 (4.92) 25.1 (6.00) 0.874
{Pearson’s chi-square test was used for categorical variables, and the Mann-Whitney test was used for continuous variables.
*Groups were paired according to sex, age, first treatment assigned and period of inclusion in the trial.
**Includes unemployment, retirement, part-time studies and unwaged domestic work. Full-time students were considered currently employed.
SD: standard deviation; SSRI: selective serotonin reuptake inhibitor; CBT: cognitive behavioral therapy; BABS: Brown Assessment of Beliefs Scale; DY-BOCS:
Dimensional Yale-Brown Obsessive-Compulsive Scale; Y-BOCS: Yale-Brown Obsessive-Compulsive Scale.
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comorbid diagnosis of agoraphobia (two abandoned group
CBT, and four terminated SSRI treatment), eighteen with
social phobia (seven abandoned group CBT, and eleven
terminated SSRI treatment), twenty with GAD (seven
abandoned group CBT, and thirteen terminated SSRI
treatment), and six with somatization disorder (one aban-
doned group CBT, and five terminated SSRI treatment). The
mean BDI scores were 18.86 (SD=13.74) and 22.75
(SD=11.24) in the group CBT and SSRI dropouts, respec-
tively, whereas the mean BAI scores were 19.86 (SD=15.11)
and 21.08 (SD=9.02) in the group CBT and SSRI dropouts,
respectively.
Many patients presented with multiple comorbidities.
Five patients who abandoned group CBT and twelve who
abandoned SSRI treatment had at least two comorbid
psychiatric disorders that were associated with noncompli-
ance.
Logistic regression model with interaction between
variables
The coefficients that were adjusted according to the
logistic regression model are shown in Table III. The p
value corresponds to the hypothesis testing H0: bi=0. In
other words, the hypothesis was that the ith variable does
not modify the chance that a specific patient abandoned
treatment. A p value , 0.05 was required to reject this
hypothesis and indicate that a given variable modified the
chance of treatment discontinuation by a specific patient.
Positive and negative coefficients indicate that the corre-
sponding variable increases or decreases the chance of
treatment discontinuation, respectively, compared with the
chance that the reference individual will do the same. The
intercept represents the reference individual, which was a
female who was allocated to pharmacological treatment,
had no diagnosis of GAD or agoraphobia and had scores of
0 on the BAI, BDI and BABS.
The results shown in Table III should be interpreted with
caution because of the large number of interactions between
variables. To clarify the impact that the values for each
variable and the scores have on the probability of treatment
discontinuation, an interactive model is available at the
following site:
http://protoc.incubadora.fapesp.br/portal/art/spreadsheet.
xls
To determine whether the model resulting from the
logistic regression was suited to predict the chance of
discontinuation, a cutoff point (0.4272) for the adjusted
probabilities was chosen so that the adjusted proportion of
dropouts in the model was the same as that presented in the
sample. If this cutoff point distinguishes between groups
with significantly different frequencies of treatment dis-
continuation, the model would be considered appropriate.
Of the 76 patients in the final sample, 66 (86.8%) were
classified correctly using the adopted cutoff point. Patients
for whom the index was above the cutoff point had a much
Table II - Psychiatric comorbidities.
Axis I Diagnosis (DSM-IV)
Completers n
(%)
Dropouts n
(%) p{
Obsessive-compulsive spectrum
disorders
11 (26.8) 14 (34.1) 0.472
Chronic tic disorders 7 (17.1) 9 (22.5) 0.540
Tourette syndrome 1 (2.4) 4 (10.0) 0.157
Body dysmorphic disorder 5 (12.2) 5 (12.5) 0.967
Trichotillomania 1 (2.7) 0 (0.0) 0.308
Mood Disorders 19 (46.3) 26 (63.4) 0.120
Major depressive disorder 15 (36.6) 20 (48.8) 0.264
Dysthymia 4 (9.8) 8 (19.5) 0.211
Bipolar type I 2 (4.9) 4 (9.8) 0.396
Bipolar type II 1 (2.4) 1 (2.4) 1,000
Anxiety Disorders 22 (53.7) 30 (73.2) 0.067
Panic disorder with
agoraphobia
0 (0.0) 3 (7.5) 0.074
Panic disorder without
agoraphobia
1 (2.4) 1 (2.5) 0.986
Agoraphobia 1 (2.4) 6 (15.0) 0.044
Social phobia 8 (19.5) 18 (45) 0.014
Specific phobia 14 (34.1) 15 (37.5) 0.753
Posttraumatic stress disorder 3 (7.3) 4 (10.0) 0.667
Generalized anxiety disorder 8 (19.5) 20 (50.0) 0.004
Somatoform disorders* 8 (19.5) 13 (31.7) 0.206
Somatization 0 (0.0) 6 (15.0) 0.010
Chronic pain disorder 2 (4.9) 3 (7.5) 0.624
Hypochondria 0 (0.0) 3 (7.5) 0.074
Conversion disorder 1 (2.4) 1 (2.5) 0.986
Eating disorders** 4 (9.8) 4 (9.8) 1,000
Impulse control disorders*** 10 (24.4) 7 (17.0) 0.332
{Pearson’s chi-square test.
*Includes body dysmorphic disorder, hypochondria, chronic pain disorder,
conversion disorder and somatization, although body dysmorphic
disorder results were shown under obsessive-compulsive spectrum
disorders.
**Includes anorexia, bulimia, binge eating and eating disorders not
otherwise specified, although only binge eating was present in the
sample.
***Includes intermittent explosive disorder (6 cases), trichotillomania (1
case), compulsive buying (5 cases), impulsive sexual behavior (1 case),
and compulsive internet use (4 cases). There were no cases of
kleptomania, pathological gambling or pyromania.
Table III - Logistic regression model with interaction
between variables
a.
coefficient Standard error p-value
Intercept
b 213.320 6.350 0.0359*
Group CBT 278.427 39.637 0.0479*
Male gender 11.439 6.537 0.0801**
BDI 0.018 0.053 0.7346
BAI 1.257 0.572 0.0279*
BABS 22.773 1.261 0.0279*
Agoraphobia 81.540 6,254.101 0.9896
GAD 10.193 6.899 0.1395
Group CBT:Male 10.781 6.084 0.0764**
Group CBT:BDI 22.344 1.111 0.0349*
Group CBT:BAI 3.148 1.504 0.0364*
Group CBT:BABS 8.106 4.038 0.0447*
Group CBT:GAD 63.596 31.004 0.0402*
Male:BAI 21.233 0.582 0.0339*
Male:BABS 2.822 1.249 0.0238*
Male:GAD 8.131 3.697 0.0278*
BAI:GAD 21.222 0.583 0.0360*
BABS:Agoraphobia 28.935 803.827 0.9911
BABS:GAD 3.014 1.283 0.0188*
aDropping out was the response variable.
bIntercept represents the reference individual (female gender, allocated
to pharmacological treatment, no diagnosis of generalized anxiety
disorder or agoraphobia and scores of 0 on the BAI, BDI and BABS).
*Statistically significant (p value , 0.05)
**Trend toward significance (p value , 0.10)
CBT: cognitive behavioral therapy; GAD: generalized anxiety disorder;
BDI: Beck Depression Inventory (score); BAI: Beck Anxiety Inventory
(score); BABS: Brown Assessment of Beliefs Scale (score).
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whom the index was below the cutoff point.
To illustrate the interactions occurring in this model, we
calculated the dropout probabilities for several hypothetical
situations:
A woman with a current diagnosis of agoraphobia and
scoring near zero on the BAI, BDI, and BABS would
have a low probability of abandoning CBT (near 0%)
and a high probability of abandoning pharmacological
treatment (near 100%).
A man with a BDI score of 55 and a BAI score of 40
would have a much higher chance of abandoning
pharmacological treatment (50%) than abandoning
CBT (near 0%). If his insight was low (BABS=12),
however, the situation would be reversed: the prob-
ability of abandoning the pharmacological treatment
(65%) would be lower than abandoning CBT (near
100%).
A woman with GAD and low insight (BABS=10)
would have a greater probability of abandoning CBT
(near 100%) than pharmacological treatment (33%).
A man with significant depressive symptoms
(BDI=30) and low insight (BABS=20) would rather
abandon CBT (near 100%) than pharmacological
treatment (42%).
DISCUSSION
Main findings
The major finding of the present study was that anxiety
disorders and somatization were associated with treatment
discontinuation in OCD patients. Many patients presented
with multiple comorbidities, which made it difficult to
distinguish the individual impacts of a given comorbidity
on noncompliance. Building a logistic regression model
inclusive of interactions made it clear that complex
interactions occurred between variables. Treatment type
(pharmacological or psychotherapeutic) interacted with
other variables to produce different probabilities of treat-
ment discontinuation.
Very few trials have investigated the clinical correlates of
treatment discontinuation in OCD patients, and no trial has
specifically addressed the impact of comorbidities on
completion rates. Therefore, we discussed our findings in
the light of psychiatric disorders other than OCD. The
relationship between the presence of anxiety disorders and
adherence to treatment has been previously addressed
20.
Among anxious patients, social phobia has been implicated
in treatment discontinuation. This observation led to the
development of distance therapeutic techniques,
21 which
have also been developed for OCD treatment.
22-23 In Food
and Drug Administration trials
6, GAD patients primarily
abandoned treatment due to side effects rather than factors
such as lack of treatment efficacy. This finding agreed with
our results that GAD patients primarily abandoned treat-
ment when allocated to pharmacological intervention.
Interestingly, SSRIs (e.g., fluoxetine) can cause an initial
worsening of anxiety symptoms during the initial phase of
treatment, which might explain the lack of treatment
compliance. We also observed that increasing the frequency
of consultations in the initial phase of the pharmacological
arm decreased the discontinuation rate. Therefore, reducing
the time interval between initial consultations might have a
positive influence on treatment compliance in highly
anxious patients. Because there was a higher completion
rate in the psychotherapeutic arm, it is also reasonable to
hypothesize that highly anxious patients are better treated
through early referrals for psychotherapy.
The present study indicates that noncompliance is an
important issue in OCD treatment in our clinical setting;
however, there are methods (e.g., psychotherapy and
frequent consultations at the beginning of pharmacother-
apy) to minimize compliance issues. Nevertheless, studies
with different populations are needed to determine whether
dropout rates are as high and as susceptible to pragmatic
measures as they were in our setting.
Somatization disorder has been shown to be a common
and chronic disorder associated with GAD, panic disorder,
and agoraphobia
24-25. Somatization disorder has also been
associated with premature antidepressant treatment dis-
continuation in patients with functional gastrointestinal
disorders or depression
26-27. Like GAD, somatization
disorder seems to increase the dropout rate associated with
intolerable side effects
27. In our sample, somatization
disorder rarely appeared without the presence of an anxiety
disorder. Therefore, we were unable to calculate the impact
of somatization disorder on dropout rates independent of
the diagnosis of a comorbid anxiety disorder. In addition,
the frequency of treatment discontinuation due to side
effects was low in our sample, which was in agreement with
the findings of a previous study
28. In addition to affecting
noncompliance associated with anxiety disorders, somatiza-
tion disorder may act as a marker of anxiety chronicity and
severity. These speculations need to be tested in future
studies.
We failed to replicate the previous findings from Mataix-
cols et al.
7 regarding the association between hoarding
symptoms and poor treatment compliance. In the test case,
5
hoarding was not associated with poor treatment response.
The present study had several limitations. Although there
was an attempt to make our sample similar to a sample from
a non-research environment, patients were sequentially
allocated to the initial treatment (with an SSRI or group
CBT) rather than choosing their initial treatment. This
difference might have negatively affected the compliance
rate. In future practical studies, other study designs should
be considered to reduce treatment discontinuation as a
consequence of dissatisfaction with the allocated interven-
tion
29. In addition, there was a subgroup of premature
dropouts (i.e., patients who abandoned treatment before
clinical evaluation) who were not represented in our
sample. Furthermore, the small sample size made it difficult
to draw any conclusions from the psychiatric comorbidities
that were infrequent in our sample, such as eating disorders,
bipolar mood disorder, and impulse control disorders.
Results regarding group CBT should also be considered
with caution because the dropout group only consisted of
sixteen patients, and findings from the regression analysis
were not evident in models that did not account for the
interactions between variables.
CONCLUSION
In conclusion, our results demonstrate that psychiatric
comorbidity among OCD, other anxiety disorders, and
somatization disorder are associated with dropout before
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392the completion of twelve weeks of treatment. Therefore,
future studies assessing measures to reduce treatment
discontinuation among patients with anxiety disorders are
needed to increase OCD treatment effectiveness.
In addition, our data suggest that treatment compliance
and effectiveness in OCD can be optimized if the assigned
treatment modality is tailored according to specific psycho-
pathologic features. Furthermore, future studies should
investigate additional strategies for treating OCD patients
with comorbid conditions.
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